Pfizer, CStone Score China's Seventh Immuno-Oncology Approval
Cejemly To Enter Crowded Market
Latest approval gives major US drug maker new foothold in China’s heated and increasingly crowded PD-1 immuno-oncology race.
You may also be interested in...
Public Company Edition: As their stock prices plummet, Adagio reshuffles its research plan and names a new CEO, while Yumanity restructures and seeks strategic alternatives. Also, Bristol sells $6bn worth of notes, Amgen issues $750m green bond, and Inhibrx and Amryt amend and refinance debt.
Multinationals including AstraZeneca are retreating from China’s overcrowded immuno-oncology market but one exception - Pfizer - remains steadfast.
As the China immuno-oncology sector becomes increasingly crowded, CStone teams up with an innovative US business partner to go global.